<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabet Med</journal-id><journal-id journal-id-type="iso-abbrev">Diabet. Med</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1464-5491</journal-id><journal-id journal-id-type="publisher-id">DME</journal-id><journal-title-group><journal-title>Diabetic Medicine</journal-title></journal-title-group><issn pub-type="ppub">0742-3071</issn><issn pub-type="epub">1464-5491</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26773557</article-id><article-id pub-id-type="pmc">5248615</article-id><article-id pub-id-type="doi">10.1111/dme.13069</article-id><article-id pub-id-type="publisher-id">DME13069</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research: Treatment</subject></subj-group><subj-group subj-group-type="heading"><subject>Research</subject><subj-group subj-group-type="heading"><subject>Treatment</subject></subj-group></subj-group></article-categories><title-group><article-title>Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (<styled-content style="fixed-case">BOOST</styled-content>
<sup>&#x000ae;</sup>: <styled-content style="fixed-case">SIMPLE USE</styled-content>)</article-title><alt-title alt-title-type="left-running-head">S. W. Park et al.</alt-title></title-group><contrib-group><contrib id="dme13069-cr-0001" contrib-type="author" corresp="yes"><name><surname>Park</surname><given-names>S. W.</given-names></name><address><email>Sungwoo0913.park@samsung.com</email></address><xref ref-type="aff" rid="dme13069-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dme13069-cr-0002" contrib-type="author"><name><surname>Bebakar</surname><given-names>W. M. W.</given-names></name><xref ref-type="aff" rid="dme13069-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dme13069-cr-0003" contrib-type="author"><name><surname>Hernandez</surname><given-names>P. G.</given-names></name><xref ref-type="aff" rid="dme13069-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dme13069-cr-0004" contrib-type="author"><name><surname>Macura</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="dme13069-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dme13069-cr-0005" contrib-type="author"><name><surname>Hersl&#x000f8;v</surname><given-names>M. L.</given-names></name><xref ref-type="aff" rid="dme13069-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dme13069-cr-0006" contrib-type="author"><name><surname>de la Rosa</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="dme13069-aff-0006">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="dme13069-aff-0001"><label><sup>1</sup></label><institution>Kangbuk Samsung Hospital</institution><named-content content-type="city">Seoul</named-content><country country="KP">Korea</country></aff><aff id="dme13069-aff-0002"><label><sup>2</sup></label><institution>Universiti Sains Malaysia Health Campus USM</institution><named-content content-type="city">Kelantan</named-content><country country="MY">Malaysia</country></aff><aff id="dme13069-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Endocrinology Service</named-content><institution>Hospital Universitario &#x02018;Dr Jos&#x000e9; E. Gonz&#x000e1;lez&#x02019;</institution><named-content content-type="city">Monterrey</named-content><country>M&#x000e9;xico</country></aff><aff id="dme13069-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Medical Affairs</named-content><institution>Novo Nordisk A/S</institution><named-content content-type="city">S&#x000f8;borg</named-content><country country="DK">Denmark</country></aff><aff id="dme13069-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Medical &#x00026; Science</named-content><institution>Novo Nordisk A/S</institution><named-content content-type="city">S&#x000f8;borg</named-content><country country="DK">Denmark</country></aff><aff id="dme13069-aff-0006"><label><sup>6</sup></label><institution>Four Rivers Clinical Research</institution><named-content content-type="city">Paducah</named-content><named-content content-type="country-part">KY</named-content><country country="US">USA</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence to</italic>: Sung Woo Park. E&#x02010;mail: <email>Sungwoo0913.park@samsung.com</email></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2017</year></pub-date><volume>34</volume><issue>2</issue><issue-id pub-id-type="doi">10.1111/dme.2017.34.issue-2</issue-id><fpage>174</fpage><lpage>179</lpage><history><date date-type="accepted"><day>11</day><month>1</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Diabetic Medicine &#x000a9; 2017 Diabetes UK <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Diabetic Medicine published by John Wiley &#x00026; Sons Ltd on behalf of Diabetes UK.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DME-34-174.pdf"/><abstract id="dme13069-abs-0001"><title>Abstract</title><sec id="dme13069-sec-0001"><title>Aims</title><p>To compare the efficacy and safety of two titration algorithms for insulin degludec/insulin aspart (<styled-content style="fixed-case">ID</styled-content>egAsp) administered once daily with metformin in participants with insulin&#x02010;na&#x000ef;ve Type 2 diabetes mellitus.</p></sec><sec id="dme13069-sec-0002"><title>Methods</title><p>This open&#x02010;label, parallel&#x02010;group, 26&#x02010;week, multicentre, treat&#x02010;to&#x02010;target trial, randomly allocated participants (1:1) to two titration arms. The Simple algorithm titrated <styled-content style="fixed-case">ID</styled-content>egAsp twice weekly based on a single pre&#x02010;breakfast self&#x02010;monitored plasma glucose (<styled-content style="fixed-case">SMPG</styled-content>) measurement. The Stepwise algorithm titrated <styled-content style="fixed-case">ID</styled-content>egAsp once weekly based on the lowest of three consecutive pre&#x02010;breakfast <styled-content style="fixed-case">SMPG</styled-content> measurements. In both groups, <styled-content style="fixed-case">ID</styled-content>egAsp once daily was titrated to pre&#x02010;breakfast plasma glucose values of 4.0&#x02013;5.0 mmol/l. Primary endpoint was change from baseline in HbA<sub>1c</sub> (%) after 26 weeks.</p></sec><sec id="dme13069-sec-0003"><title>Results</title><p>Change in HbA<sub>1c</sub> at Week 26 was <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Simple</sub> &#x02212;14.6 mmol/mol (&#x02212;1.3%) (to 52.4 mmol/mol; 6.9%) and <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Stepwise</sub> &#x02212;11.9 mmol/mol (&#x02212;1.1%) (to 54.7 mmol/mol; 7.2%). The estimated between&#x02010;group treatment difference was &#x02212;1.97 mmol/mol [95% confidence interval (<styled-content style="fixed-case">CI</styled-content>) &#x02212;4.1, 0.2] (&#x02212;0.2%, 95% <styled-content style="fixed-case">CI</styled-content> &#x02212;0.4, 0.02), confirming the non&#x02010;inferiority of <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Simple</sub> to <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Stepwise</sub> (non&#x02010;inferiority limit of &#x02264; 0.4%). Mean reduction in fasting plasma glucose and 8&#x02010;point <styled-content style="fixed-case">SMPG</styled-content> profiles were similar between groups. Rates of confirmed hypoglycaemia were lower for <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Stepwise</sub> [2.1 per patient years of exposure (<styled-content style="fixed-case">PYE</styled-content>)] vs. <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Simple</sub> (3.3 <styled-content style="fixed-case">PYE</styled-content>) (estimated rate ratio <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Simple</sub>/<styled-content style="fixed-case">ID</styled-content>egAsp<sub>Stepwise</sub> 1.8; 95% <styled-content style="fixed-case">CI</styled-content> 1.1, 2.9). Nocturnal hypoglycaemia rates were similar between groups. No severe hypoglycaemic events were reported.</p></sec><sec id="dme13069-sec-0004"><title>Conclusions</title><p>In participants with insulin&#x02010;na&#x000ef;ve Type 2 diabetes mellitus, the <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Simple</sub> titration algorithm improved HbA<sub>1c</sub> levels as effectively as a Stepwise titration algorithm. Hypoglycaemia rates were lower in the Stepwise arm.</p></sec></abstract><abstract abstract-type="short" id="dme13091-abs-0002"><title>What's new?</title><p>
<list list-type="bullet" id="dme13069-list-0001"><list-item><p>The co&#x02010;formulation, insulin degludec/insulin aspart (IDegAsp), provides basal and mealtime insulin coverage in a single injection.</p></list-item><list-item><p>IDegAsp may be titrated using two titration algorithms, Simple (titrated twice weekly) or Stepwise (titrated once weekly). Both algorithms effectively reduce HbA<sub>1c</sub> levels in participants with insulin&#x02010;na&#x000ef;ve Type 2 diabetes, with similar rates of nocturnal hypoglycaemia and no reported severe hypoglycaemic events. IDegAsp<sub>Stepwise</sub> leads to significantly lower rates of overall confirmed hypoglycaemia compared with IDegAsp<sub>Simple</sub>.</p></list-item><list-item><p>Optimizing titration may facilitate better disease management by healthcare professionals and people with diabetes.</p></list-item></list>
</p></abstract><funding-group><award-group><funding-source>Novo Nordisk A/S</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="6"/><word-count count="3462"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dme13069</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.2 mode:remove_FC converted:20.01.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dme13069-cit-1001">
<source>Diabet. Med.</source>
<volume>34</volume>: <fpage>174</fpage>&#x02013;<lpage>179</lpage> (<year>2017</year>)<pub-id pub-id-type="pmid">26773557</pub-id></mixed-citation>
</p></notes><notes><fn-group id="dme13069-ntgp-00015"><fn id="dme13069-note-1001"><p>(Clinical Trials Registry No; NCT 01365507)</p></fn></fn-group></notes></front><body><p>
<boxed-text position="anchor" content-type="box" id="dme13069-blkfxd-0001" orientation="portrait"><caption><title>What's new?</title></caption><p>
<list list-type="bullet" id="dme13069-list-0101"><list-item><p>The co&#x02010;formulation, insulin degludec/insulin aspart (IDegAsp), provides basal and mealtime insulin coverage in a single injection.</p></list-item><list-item><p>IDegAsp may be titrated using two titration algorithms, Simple (titrated twice weekly) or Stepwise (titrated once weekly). Both algorithms effectively reduce HbA<sub>1c</sub> levels in participants with insulin&#x02010;na&#x000ef;ve Type 2 diabetes, with similar rates of nocturnal hypoglycaemia and no reported severe hypoglycaemic events. IDegAsp<sub>Stepwise</sub> leads to significantly lower rates of overall confirmed hypoglycaemia compared with IDegAsp<sub>Simple</sub>.</p></list-item><list-item><p>Optimizing titration may facilitate better disease management by healthcare professionals and people with diabetes.</p></list-item></list>
</p></boxed-text>
</p><sec id="dme13069-sec-0006"><title>Introduction</title><p>People with diabetes who require intensified (prandial and basal) insulin therapy can find it challenging to manage separate basal and bolus injections, which may become a barrier to adherence to treatment <xref rid="dme13069-bib-0001" ref-type="ref">1</xref>. Regular self&#x02010;monitored plasma glucose (SMPG) allows people with diabetes to adjust their insulin dose as necessary according to titration algorithms in order to maintain appropriate glycaemic control. However, SMPG can be perceived as burdensome and incurs significant healthcare costs <xref rid="dme13069-bib-0002" ref-type="ref">2</xref>, <xref rid="dme13069-bib-0003" ref-type="ref">3</xref>. In order to improve adherence to insulin treatments, and to reduce the burden associated with multidose insulin regimens, novel insulins designed to have a longer duration of action and lower variability with reduced episodes of hypoglycaemia may allow for a clinically simplified treatment regimen for physicians and people with diabetes alike <xref rid="dme13069-bib-0004" ref-type="ref">4</xref>. Insulin degludec/insulin aspart (IDegAsp) is a soluble insulin co&#x02010;formulation of insulin degludec (IDeg, 70%), a basal insulin with a stable, ultra&#x02010;long duration of action, combined with insulin aspart (IAsp, 30%), a rapid&#x02010;acting bolus insulin <xref rid="dme13069-bib-0005" ref-type="ref">5</xref>, <xref rid="dme13069-bib-0006" ref-type="ref">6</xref>, in a single injection. IDegAsp can be administered once or twice daily with main meal(s). The aim of this study (BOOST<sup>&#x000ae;</sup>: SIMPLE USE) was to compare the efficacy and safety of two self&#x02010;titration algorithms (Simple &#x02013; self&#x02010;titration performed twice weekly with 3&#x02013;4 days between titrations; and Stepwise &#x02013; self&#x02010;titration performed once weekly) for IDegAsp administered once daily with a main meal plus metformin in participants with insulin&#x02010;na&#x000ef;ve Type 2 diabetes mellitus, inadequately controlled on oral anti&#x02010;diabetic drugs alone. This was done by comparing the difference in change from baseline in HbA<sub>1c</sub> after 26 weeks of treatment between IDegAsp once daily using the Simple titration algorithm + metformin and IDegAsp once daily using the Stepwise algorithm + metformin to a non&#x02010;inferiority limit of 0.4% (&#x02264; 4 mmol/mol).</p></sec><sec id="dme13069-sec-0007"><title>Participants and methods</title><p>The study (BOOST<sup>&#x000ae;</sup>: SIMPLE USE) was a 26&#x02010;week, multinational, multicentre, randomized, open&#x02010;label, stratified, two&#x02010;arm, parallel&#x02010;group, treat&#x02010;to&#x02010;target Phase 3b trial that compared the efficacy and safety of two titration algorithms for IDegAsp once daily, in combination with metformin (&#x02265; 1000 mg/day) in participants with insulin&#x02010;na&#x000ef;ve Type 2 diabetes mellitus inadequately treated with oral anti&#x02010;diabetic drugs alone. The study was conducted in accordance with the Declaration of Helsinki and with the International Conference on Harmonisation Guidelines for Good Clinical Practice. Approval was obtained from appropriate ethics committees and written consent was given by all participants before the start of any study&#x02010;related procedures.</p><p>Eligible participants were insulin&#x02010;na&#x000ef;ve men and women aged &#x02265; 18 years with a diagnosis of Type 2 diabetes mellitus for &#x02265; 24 weeks prior to randomization, HbA<sub>1c</sub> 53&#x02013;86 mmol/mol (7.0&#x02013;10.0%) (both inclusive), BMI &#x02264; 45.0 kg/m<sup>2</sup>, and currently treated with metformin monotherapy or metformin in any combination with one or two additional oral anti&#x02010;diabetic drugs, including sulfonylurea/glinide, dipeptidyl peptidase 4 inhibitors, &#x003b1;&#x02013;glucosidase inhibitors, thiazolidinediones, all with unchanged dosing for at least 12 weeks prior to randomization. Key exclusion criteria included treatment with a glucagon&#x02010;like peptide&#x02013;1 receptor agonist in the previous 12 weeks or diagnosis of a life&#x02010;threatening disease.</p><p>Eligible participants were randomized (1:1) to one of the two IDegAsp titration algorithms: Simple (IDegAsp<sub>Simple</sub>) or Stepwise (IDegAsp<sub>Stepwise</sub>). For IDegAsp<sub>Simple</sub>, participants titrated their insulin dose twice weekly using 2&#x02013;U increments or decrements based on a single pre&#x02010;breakfast SMPG measurement on the day of titration (Table S1). For IDegAsp<sub>Stepwise</sub>, participants titrated their insulin dose once weekly using increments or decrements of 2&#x02013;8 U based on the lowest of three consecutive pre&#x02010;breakfast SMPG readings (2 days before, and on the day of titration) (Table S2). In both groups, the IDegAsp dose was titrated to achieve pre&#x02010;breakfast plasma glucose values of 4.0&#x02013;5.0 mmol/l (71&#x02013;90 mg/dl). IDegAsp was administered once daily with a main meal at a starting dose of 10 U in both titration groups. Any changes in injection schedule were guided by a physician during either a visit or telephone contact. Participants continued on the same dose of metformin; all other oral anti&#x02010;diabetic drugs were discontinued before the start of the trial.</p><p>The primary endpoint was the change in HbA<sub>1c</sub> (%) from baseline to after 26 weeks of treatment, using a non&#x02010;inferiority limit of 0.4% (&#x02264; 4 mmol/mol). Secondary efficacy endpoints included change in fasting plasma glucose from baseline, the proportion of participants who achieved HbA<sub>1c</sub> targets and 8&#x02010;point SMPG profiles. Secondary safety endpoints included insulin dose, body weight, adverse events and hypoglycaemic episodes. Confirmed hypoglycaemic episodes included those with a plasma glucose value &#x0003c; 3.1 mmol/l (56 mg/dl) and/or severe hypoglycaemic episodes (in which the participant required assistance). Hypoglycaemic episodes that occurred between 00.01 and 05.59 h (both inclusive) were classified as nocturnal. All endpoints were analysed as detailed in the Supporting Information (statistical analyses).</p></sec><sec id="dme13069-sec-0008"><title>Results</title><p>Of 276 participants, 136 were randomly allocated to the IDegAsp<sub>Simple</sub> group and 140 to the IDegAsp<sub>Stepwise</sub> group. Baseline characteristics (Table<xref rid="dme13069-tbl-0001" ref-type="table-wrap">1</xref>) and participant disposition (Fig. S1) were similar in the two groups.</p><table-wrap id="dme13069-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of participants (full analysis set)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="top" rowspan="1" colspan="1">IDegAsp<sub>Simple</sub> (<italic>n</italic> = 136)</th><th align="center" valign="top" rowspan="1" colspan="1">IDegAsp<sub>Stepwise</sub> (<italic>n</italic> = 140)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Female/male, %</td><td align="char" char="." rowspan="1" colspan="1">43.4/56.6</td><td align="char" char="." rowspan="1" colspan="1">60.0/40.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Race: white/black/Asian/other, %</td><td align="char" char="." rowspan="1" colspan="1">55.9/10.3/33.8/0.0</td><td align="char" char="." rowspan="1" colspan="1">59.3/15.0/23.5/2.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Ethnicity: Hispanic or Latin American, %</td><td align="char" char="." rowspan="1" colspan="1">27.2</td><td align="char" char="." rowspan="1" colspan="1">28.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years (<sc>sd</sc>)</td><td align="char" char="." rowspan="1" colspan="1">57.0 (&#x000b1; 9.4)</td><td align="char" char="." rowspan="1" colspan="1">55.8 (&#x000b1; 9.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg (<sc>sd</sc>)</td><td align="char" char="." rowspan="1" colspan="1">85.1 (&#x000b1; 17.3)</td><td align="char" char="." rowspan="1" colspan="1">83.2 (&#x000b1; 21.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup> (<sc>sd</sc>)</td><td align="char" char="." rowspan="1" colspan="1">31.0 (&#x000b1; 5.0)</td><td align="char" char="." rowspan="1" colspan="1">30.8 (&#x000b1; 6.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of diabetes, years (<sc>sd</sc>)</td><td align="char" char="." rowspan="1" colspan="1">10.1 (&#x000b1; 6.5)</td><td align="char" char="." rowspan="1" colspan="1">10.2 (&#x000b1; 6.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA<sub>1c</sub>, mmol/mol (<sc>sd</sc>)</td><td align="char" char="." rowspan="1" colspan="1">66.9 (&#x000b1; 8.9)</td><td align="char" char="." rowspan="1" colspan="1">66.6 (&#x000b1; 8.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA<sub>1c</sub>, % (<sc>sd</sc>)</td><td align="char" char="." rowspan="1" colspan="1">8.3 (&#x000b1; 0.8)</td><td align="char" char="." rowspan="1" colspan="1">8.2 (&#x000b1; 0.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose, mmol/l (<sc>sd</sc>)</td><td align="char" char="." rowspan="1" colspan="1">8.9 (&#x000b1; 2.4)</td><td align="char" char="." rowspan="1" colspan="1">9.0 (&#x000b1; 2.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose, mg/dl (<sc>sd</sc>)</td><td align="char" char="." rowspan="1" colspan="1">159.7 (&#x000b1; 44.1)</td><td align="char" char="." rowspan="1" colspan="1">162.1 (&#x000b1; 42.0)</td></tr></tbody></table><table-wrap-foot><fn id="dme13069-note-0001"><p>IDegAsp, insulin degludec/insulin aspart.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><sec id="dme13069-sec-0009"><title>Efficacy</title><p>The observed mean HbA<sub>1c</sub> decreased from 67.2 (&#x000b1; 8.7) mmol/mol [8.3 (&#x000b1; 0.8)%] to 52.4 (&#x000b1; 10.7) mmol/mol [6.9 (&#x000b1; 1.0)%] in the IDegAsp<sub>Simple</sub> group and from 66.9 (&#x000b1; 8.9) mmol/mol [8.2 (&#x000b1; 0.8)%] to 54.7 (&#x000b1; 10.3) mmol/mol [7.2 (&#x000b1; 0.9)%] in the IDegAsp<sub>Stepwise</sub> group after 26 weeks of treatment. The mean reductions in HbA<sub>1c</sub> from baseline to 26 weeks (primary endpoint) were &#x02212;14.6 mmol/mol (&#x02212;1.3%; IDegAsp<sub>Simple</sub>) and &#x02212;11.9 mmol/mol (&#x02212;1.1%; IDegAsp<sub>Stepwise</sub>) (full analysis set; Fig. <xref rid="dme13069-fig-0001" ref-type="fig">1</xref>a). The estimated between&#x02010;group treatment difference (ETD) was &#x02212;2.0 mmol/mol [95% confidence interval (CI) &#x02212;4.1, 0.2] [&#x02212;0.2% (95% CI &#x02212;0.4, 0.02)], confirming non&#x02010;inferiority of IDegAsp<sub>Simple</sub> vs. IDegAsp<sub>Stepwise</sub>.</p><fig fig-type="Figure" xml:lang="en" id="dme13069-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Efficacy of treatment with <styled-content style="fixed-case">ID</styled-content>egAsp in people with Type 2 diabetes mellitus titrated using either a Simple (<styled-content style="fixed-case">ID</styled-content>egAsp<sub>Simple</sub>) or a Stepwise (<styled-content style="fixed-case">ID</styled-content>egAsp<sub>Stepwise</sub>) dose&#x02010;titration algorithm measured in terms of: (a) mean HbA<sub>1c</sub> with <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Simple</sub> and <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Stepwise</sub> over 26 weeks (full analysis set), (b) mean fasting plasma glucose (<styled-content style="fixed-case">FPG</styled-content>) with <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Simple</sub> and <styled-content style="fixed-case">ID</styled-content>egAsp<sub>Stepwise</sub> over 26 weeks (full analysis set), and (c) daily insulin dose by treatment week (safety analysis set). The full analysis set included all participants randomized and the safety analysis set included all participants who received at least one dose of <styled-content style="fixed-case">ID</styled-content>egAsp. Missing data were imputed using the last observation carried forward approach. *Data are mean (<sc>sd</sc>); treatment differences are derived from an <styled-content style="fixed-case">LS</styled-content> means&#x02010;based model. <sup>&#x02020;</sup>Calculated, not measured. CI, confidence interval; ETD, estimated treatment difference; FPG, fasting plasma glucose; HbA<sub>1c</sub>, glycated haemoglobin; IDegAsp, insulin degludec/insulin aspart; LS, least squares; SD, standard deviation; U, unit.</p></caption><graphic id="nlm-graphic-1" xlink:href="DME-34-174-g001"/></fig><p>There were no significant differences in the mean reduction in fasting plasma glucose between the two groups [ETD &#x02212;0.4 mmol/l; 95% CI &#x02212;0.9, 0.09 (&#x02212;7.6 mg/dl; 95% CI &#x02212;16.7, 1.6)] (Fig. <xref rid="dme13069-fig-0001" ref-type="fig">1</xref>b). The statistical analyses of the 8&#x02010;point SMPG showed no statistically significant differences between groups at any of the measured time points. Similarly, the prandial glucose increment after 26 weeks showed no statistically significant differences between groups at any of the measured time points (Figs S2 and S3). The mean daily insulin dose was similar in both groups at baseline; however, by Week 26, the mean daily insulin dose was 0.7 U/kg in the IDegAsp<sub>Simple</sub> group vs. 0.7 U/kg in the IDegAsp<sub>Stepwise</sub> group (mean dose ratio of 1.11 U/kg) (Fig. <xref rid="dme13069-fig-0001" ref-type="fig">1</xref>c). The observed proportion of participants who achieved the American Diabetes Association&#x02010;recommended HbA<sub>1c</sub> target of &#x0003c; 7% at the end of the trial was 58.1% in the IDegAsp<sub>Simple</sub> group and 49.3% in the IDegAsp<sub>Stepwise</sub> group. The proportion of participants who achieved HbA<sub>1c</sub> targets of &#x0003c; 53 mmol/mol (&#x0003c; 7.0%) without confirmed hypoglycaemia in the last 12 weeks of the trial was 39.5% for IDegAsp<sub>Simple</sub> and 30.7% for IDegAsp<sub>Stepwise</sub>, a difference that was statistically not significant.</p></sec><sec id="dme13069-sec-0010"><title>Safety</title><p>At Week 26, mean increase in body weight from baseline was higher for IDegAsp<sub>Simple</sub> than for IDegAsp<sub>Stepwise</sub>, but this was not statistically significant (2.6 and 1.9 kg, respectively; ETD 0.9 kg; 95% CI &#x02212;0.1, 1.8).</p><p>Overall, 46.3% and 38.6% of participants reported confirmed hypoglycaemia in the IDegAsp<sub>Simple</sub> and IDegAsp<sub>Stepwise</sub> groups, respectively. The rates of overall confirmed hypoglycaemia were significantly lower for IDegAsp<sub>Stepwise</sub> than for IDegAsp<sub>Simple</sub> [2.1 and 3.3 episodes/patient years of exposure (PYE), respectively; estimated rate ratio (ERR) 1.8; 95% CI 1.1, 2.9]. Similar proportions of participants reported nocturnal confirmed hypoglycaemic episodes for IDegAsp<sub>Simple</sub> and IDegAsp<sub>Stepwise</sub> (13.4% and 12.9%, respectively; 0.5 and 0.4 episodes/PYE, respectively; ERR 1.1; 95% CI 0.5, 2.4). No severe hypoglycaemic episodes were reported.</p><p>The proportions of participants in each group with reported treatment&#x02010;emergent adverse events were 53.7% for IDegAsp<sub>Simple</sub> and 63.6% for IDegAsp<sub>Stepwise</sub> (Table S3).</p></sec></sec><sec id="dme13069-sec-0011"><title>Discussion</title><p>This 26&#x02010;week study demonstrated that IDegAsp administered once daily and titrated twice weekly using a simple algorithm effectively improved HbA<sub>1c</sub> levels, and was non&#x02010;inferior to IDegAsp once daily titrated once weekly using a stepwise titration algorithm. Effective glycaemic control was achieved according to current treatment guidelines <xref rid="dme13069-bib-0007" ref-type="ref">7</xref>, including achievement of target HbA<sub>1c</sub> levels of 52.4 mmol/mol (6.9%) and 54.7 mmol/mol (7.2%) for IDegAsp<sub>Simple</sub> and IDegAsp<sub>Stepwise</sub>, after 26 weeks of treatment, a reduction from 66.9 mmol/mol (8.3%) and 66.6 mmol/mol (8.2%) at baseline for IDegAsp<sub>Simple</sub> and IDegAsp<sub>Stepwise</sub>, respectively. Fewer than half of the participants in both arms achieved HbA<sub>1c</sub> &#x0003c; 53 mmol/mol (&#x0003c; 7.0%) without confirmed hypoglycaemia during the trial. The reduction in HbA<sub>1c</sub> from baseline was similar to that seen in people with Type 2 diabetes mellitus na&#x000ef;ve to insulin, where twice&#x02010;daily IDegAsp was non&#x02010;inferior in lowering HbA<sub>1c</sub>, compared with twice&#x02010;daily biphasic insulin aspart 30 (BIAsp 30), but was superior in lowering fasting plasma glucose from baseline after 26 weeks, and significantly reduced overall confirmed hypoglycaemia <xref rid="dme13069-bib-0008" ref-type="ref">8</xref>. This was also consistent with recent reports in Japanese people with Type 2 diabetes mellitus, demonstrating the superiority of IDegAsp once daily in lowering mean HbA<sub>1c</sub> vs. insulin glargine (IGlar) <xref rid="dme13069-bib-0009" ref-type="ref">9</xref>. When administered once or twice daily in people with Type 2 diabetes mellitus previously treated with insulin, IDegAsp demonstrated non&#x02010;inferiority to BIAsp 30 in lowering HbA<sub>1c</sub> from baseline at 26 weeks, with the proportion of participants achieving HbA<sub>1c</sub> targets of &#x0003c; 53 mmol/mol (&#x0003c; 7.0%) being 50.4% in the IDegAsp group and 48.6% in the BIAsp 30 group <xref rid="dme13069-bib-0010" ref-type="ref">10</xref>. The odds of achieving an HbA<sub>1c</sub> target of &#x0003c; 53 mmol/mol (&#x0003c; 7.0%) without hypoglycaemic episodes during the last 12 weeks of the study were higher for IDegAsp (21% of patients) than for BIAsp 30 (14% of participants) <xref rid="dme13069-bib-0010" ref-type="ref">10</xref>.</p><p>Given that participants entering the trial were insulin&#x02010;na&#x000ef;ve, the percentage of participants with overall confirmed hypoglycaemia observed in both titration groups was not unexpected (IDegAsp<sub>Stepwise</sub> 38.6% vs. IDegAsp<sub>Simple</sub> 46.3%). A similar number has been observed in a previous trial in participants with insulin&#x02010;na&#x000ef;ve Type 2 diabetes mellitus treated with IDegAsp once daily, where the proportion of participants reporting at least one confirmed hypoglycaemia episode during the treatment period was 44% (with both IDegAsp and IGlar) <xref rid="dme13069-bib-0009" ref-type="ref">9</xref>. Notably, however, no participants experienced severe hypoglycaemia in this trial. Together, these findings highlight the effectiveness and safety of treatment with IDegAsp once daily in people with insulin&#x02010;na&#x000ef;ve Type 2 diabetes mellitus.</p><p>The rate of confirmed hypoglycaemia was numerically lower for IDegAsp<sub>Simple</sub> (3.3 events/PYE; 46.3% of participants) vs. IDegAsp<sub>Stepwise</sub> (2.1 events/PYE; 38.6% of participants). This reduction with IDegAsp once daily was previously reported in the aforementioned trial in Japanese people with Type 2 diabetes mellitus in which IDegAsp once&#x02010;daily treatment was associated with numerically lower rates of overall confirmed hypoglycaemia vs. IGlar (IDegAsp: 1.9 events/PYE vs. IGlar 2.7 events/PYE) <xref rid="dme13069-bib-0009" ref-type="ref">9</xref>. As mentioned above, in a population with uncontrolled Type 2 diabetes mellitus previously treated with once&#x02010; or twice&#x02010;daily insulin, IDegAsp administration (twice daily) reduced confirmed hypoglycaemia vs. BIAsp 30 [9.7 vs. 14.0 episodes/PYE for IDegAsp and BIAsp 30 groups, respectively; ERR 0.7 (95% CI 0.5&#x02013;0.9), <italic>P</italic> = 0.0049] <xref rid="dme13069-bib-0010" ref-type="ref">10</xref>.</p><p>The more conservative nature of the Stepwise algorithm may explain the lower rates of overall confirmed hypoglycaemia and the lower mean daily insulin dose in the Stepwise arm. According to the Simple algorithm, dose adjustment was based on a single SMPG measurement rather than the lowest of three measurements required by the Stepwise algorithm, meaning that there was always a possibility that dose adjustments in the Simple arm were made based on a random high SMPG value.</p><p>The percentage of participants with adverse events in both groups was 53.7% for the IDegAsp<sub>Simple</sub> group vs. 63.6% for the IDegAsp<sub>Stepwise</sub> group. IDegAsp was well tolerated in both titration groups and no safety issues were identified during the trial.</p><p>These results provide insights into two possible titration methods that may be suitable for use with IDegAsp. For people with diabetes who are inadequately controlled on oral anti&#x02010;diabetic drugs alone, and who require transition to insulin therapy, these methods potentially offer physicians the option to administer a personalized insulin titration regimen that is tailored to individual needs.</p></sec><sec id="dme13069-sec-0012"><title>Funding sources</title><p>This study was funded by Novo Nordisk A/S.</p></sec><sec id="dme13069-sec-0013"><title>Competing interests</title><p>S.W. Park has received research support from Novo Nordisk. R. de la Rosa has been a member of speaker bureaux for Novo Nordisk, Sanofi&#x02010;Aventis, AstraZeneca, Boehringer Ingelheim, and AbbVie. He has also received clinical research support from Novo Nordisk, Sanofi&#x02010;Aventis, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, and GlaxoSmith&#x02010;Kline. S. Macura is an employee of Novo Nordisk A/S. W.M.W. Bebakar has been a member of advisory panels and speaker bureaux for Novo Nordisk. P.G. Hernandez has been a consultant for Amgen and Eli Lilly. He has also received clinical research support from Novo Nordisk, Amgen, Eli Lilly, Bristol&#x02010;Myers Squibb, and MSD. M.L. Hersl&#x000f8;v is an employee of Novo Nordisk A/S.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Figure S1</bold>. Disposition of participants.</p><p>
<bold>Figure S2</bold>. Efficacy of IDegAsp using either a simple (IDegAsp<sub>Simple</sub>) or a Stepwise (IDegAsp<sub>Stepwise</sub>) dose&#x02010;titration algorithm, as measured by an 8&#x02010;point self&#x02010;monitored plasma glucose profile at baseline and Week 26.</p><p>
<bold>Figure S3</bold>. Efficacy of IDegAsp using either a Simple (IDegAsp<sub>Simple</sub>) or a Stepwise (IDegAsp<sub>Stepwise</sub>) dose&#x02010;titration algorithm as measured by prandial glucose increments at Week 26.</p><p>
<bold>Table S1</bold>. IDegAsp<sub>Simple</sub> titration algorithm.</p><p>
<bold>Table S2</bold>. IDegAsp<sub>Stepwise</sub> titration algorithm.</p><p>
<bold>Table S3</bold>. Summary of adverse events.</p></caption><media xlink:href="DME-34-174-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dme13069-sec-0014"><title>Acknowledgements</title><p>Medical writing support was provided by apothecom scopemedical ltd, funded by Novo Nordisk A/S. This study was funded by Novo Nordisk A/S (ClinicalTrials.gov identifier NCT01365507).</p></ack><ref-list content-type="cited-references" id="dme13069-bibl-0001"><title>References</title><ref id="dme13069-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dme13069-cit-0001">
<string-name>
<surname>Mosenzon</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Raz</surname>
<given-names>I</given-names>
</string-name>. <article-title>Intensification of insulin therapy for type 2 diabetic patients in primary care: basal&#x02010;bolus regimen versus premix insulin analogs when and for whom?</article-title>
<source>Diabetes Care</source>
<year>2013</year>; <volume>36</volume>(<issue>Suppl 2</issue>): <fpage>S212</fpage>&#x02013;<lpage>S218</lpage>.<pub-id pub-id-type="pmid">23882048</pub-id></mixed-citation></ref><ref id="dme13069-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dme13069-cit-0002">
<string-name>
<surname>Yeaw</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>Wolden</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Christensen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Groleau</surname>
<given-names>D</given-names>
</string-name>. <article-title>Cost of self&#x02010;monitoring of blood glucose in Canada among patients on an insulin regimen for diabetes</article-title>. <source>Diabetes Ther Res Treat Educ Diabetes Relat Disord</source>
<year>2012</year>; <volume>3</volume>: <fpage>7</fpage>.</mixed-citation></ref><ref id="dme13069-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dme13069-cit-0003">
<string-name>
<surname>Yeaw</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>WC</given-names>
</string-name>, <string-name>
<surname>Aagren</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Christensen</surname>
<given-names>T</given-names>
</string-name>. <article-title>Cost of self&#x02010;monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes</article-title>. <source>J Manag Care Pharm</source>
<year>2012</year>; <volume>18</volume>: <fpage>21</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">22235952</pub-id></mixed-citation></ref><ref id="dme13069-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dme13069-cit-0004">
<string-name>
<surname>Unnikrishnan</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Bantwal</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sahay</surname>
<given-names>RK</given-names>
</string-name>. <article-title>Translating structure to clinical properties of an ideal basal insulin</article-title>. <source>J Assoc Physicians India</source>
<year>2014</year>; <volume>62</volume>(<issue>1 Suppl</issue>): <fpage>15</fpage>&#x02013;<lpage>20</lpage>.</mixed-citation></ref><ref id="dme13069-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dme13069-cit-0005">
<string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nosek</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>B&#x000f8;ttcher</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Hastrup</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Haahr</surname>
<given-names>H</given-names>
</string-name>. <article-title>Ultra&#x02010;long&#x02010;acting insulin degludec has a flat and stable glucose&#x02010;lowering effect in type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>
<year>2012</year>; <volume>14</volume>: <fpage>944</fpage>&#x02013;<lpage>950</lpage>.<pub-id pub-id-type="pmid">22726241</pub-id></mixed-citation></ref><ref id="dme13069-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dme13069-cit-0006">
<string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nosek</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Roepstorff</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chenji</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Haahr</surname>
<given-names>H</given-names>
</string-name>. <article-title>Distinct prandial and basal glucose&#x02010;lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus</article-title>. <source>Diabetes Ther</source>
<year>2014</year>; <volume>5</volume>: <fpage>255</fpage>&#x02013;<lpage>265</lpage>.<pub-id pub-id-type="pmid">24888255</pub-id></mixed-citation></ref><ref id="dme13069-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dme13069-cit-0007">
<string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Diamant</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ferrannini</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>
<italic>et al</italic>
<article-title>Management of hyperglycemia in type 2 diabetes: a patient&#x02010;centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title>. <source>Diabetes Care</source>
<year>2012</year>; <volume>35</volume>: <fpage>1364</fpage>&#x02013;<lpage>1379</lpage>.<pub-id pub-id-type="pmid">22517736</pub-id></mixed-citation></ref><ref id="dme13069-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dme13069-cit-0008">
<string-name>
<surname>Franek</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Haluzik</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Canecki</surname>
<given-names>Varzic S</given-names>
</string-name>, <string-name>
<surname>Sargin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Macura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zacho</surname>
<given-names>J</given-names>
</string-name>
<italic>et al</italic>
<article-title>Twice&#x02010;daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin&#x02010;na&#x00131;ve adults with Type 2 diabetes</article-title>. <source>Diabet Med</source>
<year>2016</year>; <volume>33</volume>: <fpage>497</fpage>&#x02013;<lpage>505</lpage>.<pub-id pub-id-type="pmid">26435365</pub-id></mixed-citation></ref><ref id="dme13069-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dme13069-cit-0009">
<string-name>
<surname>Onishi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ono</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Rab&#x000f8;l</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Endahl</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</string-name>. <article-title>Superior glycaemic control with once&#x02010;daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial</article-title>. <source>Diabetes Obes Metab</source>
<year>2013</year>; <volume>15</volume>: <fpage>826</fpage>&#x02013;<lpage>832</lpage>.<pub-id pub-id-type="pmid">23557077</pub-id></mixed-citation></ref><ref id="dme13069-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dme13069-cit-0010">
<string-name>
<surname>Fulcher</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Christiansen</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Bantwal</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Palazewska&#x02010;Muszynska</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mersebach</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>TH</given-names>
</string-name>
<italic>et al</italic>
<article-title>Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin&#x02010;treated type 2 diabetes: a phase 3a, randomized, treat&#x02010;to&#x02010;target trial</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>2084</fpage>&#x02013;<lpage>2090</lpage>.<pub-id pub-id-type="pmid">24812432</pub-id></mixed-citation></ref></ref-list></back></article>